Molecular imaging of plaque vulnerability

Journal of Nuclear Cardiology

Volumn 21, Issue 6, 2014, Pages 1112-1128

  Tavakoli, Sina ^a   Vashist, Aseem ^b,d   Sadeghi, Mehran M ^c,d  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b UNIVERSITY OF CONNECTICUT SCHOOL OF MEDICINE   (United States)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

Author keywords

angiogenesis; apoptosis; Atherosclerosis; inflammation; molecular imaging

Indexed keywords

RADIOPHARMACEUTICAL AGENT;

ATHEROSCLEROSIS; CASE REPORT; COMPUTER ASSISTED DIAGNOSIS; COMPUTER ASSISTED EMISSION TOMOGRAPHY; HUMAN; IMAGE ENHANCEMENT; MALE; METABOLISM; MIDDLE AGED; MOLECULAR IMAGING; PROCEDURES; RISK ASSESSMENT; SCINTISCANNING;

ATHEROSCLEROSIS; HUMANS; IMAGE ENHANCEMENT; IMAGE INTERPRETATION, COMPUTER-ASSISTED; MALE; MIDDLE AGED; MOLECULAR IMAGING; RADIOPHARMACEUTICALS; RISK ASSESSMENT; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 84939872357     PISSN: 10713581     EISSN: 15326551     Source Type: Journal    
DOI: 10.1007/s12350-014-9959-4     Document Type: Article

References (80)

1. Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Borden WB, et al. Heart disease and stroke statistics—2013 update: A report from the American Heart Association. Circulation 2013;127:e6-245.
2. Libby P. Mechanisms of acute coronary syndromes and their implications for therapy. N Engl J Med 2013;368:2004-13.
3. Boden WE, O’Rourke RA, Teo KK, Hartigan PM, Maron DJ, Kostuk WJ, et al. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med 2007;356:1503-16.
4. BARI 2D Study Group, Frye RL, August P, Brooks MM, Hardison RM, Kelsey SF, et al. A randomized trial of therapies for type 2 diabetes and coronary artery disease. N Engl J Med 2009;360:2503-15.
5. Jeremias A, Kaul S, Rosengart TK, Gruberg L, Brown DL. The impact of revascularization on mortality in patients with nonacute coronary artery disease. Am J Med 2009;122:152-61.
6. Weber C, Noels H. Atherosclerosis: Current pathogenesis and therapeutic options. Nat Med 2011;17:1410-22.
7. Sadeghi MM. The pathobiology of the vessel wall: Implications for imaging. J Nucl Cardiol 2006;13:402-14.
8. Falk E, Nakano M, Bentzon JF, Finn AV, Virmani R. Update on acute coronary syndromes: The pathologists’ view. Eur Heart J 2013;34:719-28.
9. Silvestre-Roig C, de Winther MP, Weber C, Daemen MJ, Lutgens E, Soehnlein O. Atherosclerotic plaque destabilization: Mechanisms, models, and therapeutic strategies. Circ Res 2014;114:214-26.
10. Swirski FK, Nahrendorf M. Leukocyte behavior in atherosclerosis, myocardial infarction, and heart failure. Science 2013;339:161-6.
11. Hong MK, Mintz GS, Lee CW, Kim YH, Lee SW, Song JM, et al. Comparison of coronary plaque rupture between stable angina and acute myocardial infarction: A three-vessel intravascular ultrasound study in 235 patients. Circulation 2004;110:928-33.
12. Hansson GK, Robertson AK, Soderberg-Naucler C. Inflammation and atherosclerosis. Ann Rev Pathol 2006;1:297-329.
13. Briley-Saebo KC, Shaw PX, Mulder WJ, Choi SH, Vucic E, Aguinaldo JG, et al. Targeted molecular probes for imaging atherosclerotic lesions with magnetic resonance using antibodies that recognize oxidation-specific epitopes. Circulation 2008;117:3206-15.
14. Kaufmann BA, Sanders JM, Davis C, Xie A, Aldred P, Sarembock IJ, et al. Molecular imaging of inflammation in atherosclerosis with targeted ultrasound detection of vascular cell adhesion molecule-1. Circulation 2007;116:276-84.
15. Cai J, Hatsukami TS, Ferguson MS, Kerwin WS, Saam T, Chu B, et al. In vivo quantitative measurement of intact fibrous cap and lipid-rich necrotic core size in atherosclerotic carotid plaque: Comparison of high-resolution, contrast-enhanced magnetic resonance imaging and histology. Circulation 2005;112:3437-44.
16. Woollard KJ, Geissmann F. Monocytes in atherosclerosis: Subsets and functions. Nat Rev Cardiol 2010;7:77-86.
17. Robbins CS, Hilgendorf I, Weber GF, Theurl I, Iwamoto Y, Figueiredo JL, et al. Local proliferation dominates lesional macrophage accumulation in atherosclerosis. Nat Med 2013;19:1166-72.
18. Gautier EL, Jakubzick C, Randolph GJ. Regulation of the migration and survival of monocyte subsets by chemokine receptors and its relevance to atherosclerosis. Arterioscler Thromb Vasc Biol 2009;29:1412-8.
19. Ingersoll MA, Platt AM, Potteaux S, Randolph GJ. Monocyte trafficking in acute and chronic inflammation. Trends Immunol 2011;32:470-7.
20. Kircher MF, Grimm J, Swirski FK, Libby P, Gerszten RE, Allport JR, et al. Noninvasive in vivo imaging of monocyte trafficking to atherosclerotic lesions. Circulation 2008;117:388-95.
21. Luehmann HP, Pressly ED, Detering L, Wang C, Pierce R, Woodard PK, et al. PET/CT imaging of chemokine receptor CCR5 in vascular injury model using targeted nanoparticle. J Nucl Med 2014;55:629-34.
22. Liu Y, Pierce R, Luehmann HP, Sharp TL, Welch MJ. PET imaging of chemokine receptors in vascular injury-accelerated atherosclerosis. J Nucl Med 2013;54:1135-41.
23. Tang TY, Muller KH, Graves MJ, Li ZY, Walsh SR, Young V, et al. Iron oxide particles for atheroma imaging. Arterioscler Thromb Vasc Biol 2009;29:1001-8.
24. Hyafil F, Cornily JC, Feig JE, Gordon R, Vucic E, Amirbekian V, et al. Noninvasive detection of macrophages using a nanoparticulate contrast agent for computed tomography. Nat Med 2007;13:636-41.
25. Moore KJ, Tabas I. Macrophages in the pathogenesis of atherosclerosis. Cell 2011;145:341-55.
26. Li D, Patel AR, Klibanov AL, Kramer CM, Ruiz M, Kang BY, et al. Molecular imaging of atherosclerotic plaques targeted to oxidized LDL receptor LOX-1 by SPECT/CT and magnetic resonance. Circ Cardiovasc Imaging 2010;3:464-72.
27. Rudd JH, Myers KS, Bansilal S, Machac J, Rafique A, Farkouh M, et al. (18)Fluorodeoxyglucose positron emission tomography imaging of atherosclerotic plaque inflammation is highly reproducible: Implications for atherosclerosis therapy trials. J Am Coll Cardiol 2007;50:892-6.
28. Tawakol A, Migrino RQ, Bashian GG, Bedri S, Vermylen D, Cury RC, et al. In vivo 18F-fluorodeoxyglucose positron emission tomography imaging provides a noninvasive measure of carotid plaque inflammation in patients. J Am Coll Cardiol 2006;48:1818-24.
29. Tahara N, Kai H, Ishibashi M, Nakaura H, Kaida H, Baba K, et al. Simvastatin attenuates plaque inflammation: Evaluation by fluorodeoxyglucose positron emission tomography. J Am Coll Cardiol 2006;48:1825-31.
30. Tawakol A, Fayad ZA, Mogg R, Alon A, Klimas MT, Dansky H, et al. Intensification of statin therapy results in a rapid reduction in atherosclerotic inflammation: Results of a multicenter fluorodeoxyglucose-positron emission tomography/computed tomography feasibility study. J Am Coll Cardiol 2013;62:909-17.
31. Sadeghi MM. 18F-FDG PET and vascular inflammation: Time to refine the paradigm? J Nucl Cardiol 2014:1-6. doi:10.1007/s12350-014-9917-1.
32. Sica A, Mantovani A. Macrophage plasticity and polarization: In vivo veritas. J Clin Invest 2012;122:787-95.
33. Stoger JL, Gijbels MJ, van der Velden S, Manca M, van der Loos CM, Biessen EA, et al. Distribution of macrophage polarization markers in human atherosclerosis. Atherosclerosis 2012;225:461-8.
34. Shaikh S, Brittenden J, Lahiri R, Brown PA, Thies F, Wilson HM. Macrophage subtypes in symptomatic carotid artery and femoral artery plaques. Eur J Vasc Endovasc Surg 2012;44:491-7.
35. Folco EJ, Sheikine Y, Rocha VZ, Christen T, Shvartz E, Sukhova GK, et al. Hypoxia but not inflammation augments glucose uptake in human macrophages implications for imaging atherosclerosis with (18)fluorine-labeled 2-deoxy-d-glucose positron emission tomography. J Am Coll Cardiol 2011;58:603-14.
36. Satomi T, Ogawa M, Mori I, Ishino S, Kubo K, Magata Y, et al. Comparison of contrast agents for atherosclerosis imaging using cultured macrophages: FDG versus ultrasmall superparamagnetic iron oxide. J Nucl Med 2013;54:999-1004.
37. Tavakoli S, Zamora D, Ullevig S, Asmis R. Bioenergetic profiles diverge during macrophage polarization: Implications for the interpretation of 18F-FDG PET imaging of atherosclerosis. J Nucl Med 2013;54:1661-7.
38. Tahara N, Mukherjee J, de Haas HJ, Petrov AD, Tawakol A, Haider N, et al. 2-deoxy-2-[(18)F]fluoro-d-mannose positron emission tomography imaging in atherosclerosis. Nat Med 2014;20:215-9.
39. Lutgens SP, Cleutjens KB, Daemen MJ, Heeneman S. Cathepsin cysteine proteases in cardiovascular disease. FASEB J 2007;21:3029-41.
40. Jaffer FA, Kim DE, Quinti L, Tung CH, Aikawa E, Pande AN, et al. Optical visualization of cathepsin K activity in atherosclerosis with a novel, protease-activatable fluorescence sensor. Circulation 2007;115:2292-8.
41. Jaffer FA, Vinegoni C, John MC, Aikawa E, Gold HK, Finn AV, et al. Real-time catheter molecular sensing of inflammation in proteolytically active atherosclerosis. Circulation 2008;118:1802-9.
42. Deguchi JO, Aikawa M, Tung CH, Aikawa E, Kim DE, Ntziachristos V, et al. Inflammation in atherosclerosis: Visualizing matrix metalloproteinase action in macrophages in vivo. Circulation 2006;114:55-62.
43. Zhang J, Nie L, Razavian M, Ahmed M, Dobrucki LW, Asadi A, et al. Molecular imaging of activated matrix metalloproteinases in vascular remodeling. Circulation 2008;118:1953-60.
44. Fujimoto S, Hartung D, Ohshima S, Edwards DS, Zhou J, Yalamanchili P, et al. Molecular imaging of matrix metalloproteinase in atherosclerotic lesions: Resolution with dietary modification and statin therapy. J Am Coll Cardiol 2008;52:1847-57.
45. Ohshima S, Petrov A, Fujimoto S, Zhou J, Azure M, Edwards DS, et al. Molecular imaging of matrix metalloproteinase expression in atherosclerotic plaques of mice deficient in apolipoprotein e or low-density-lipoprotein receptor. J Nucl Med 2009;50:612-7.
46. Razavian M, Nie L, Challa A, Zhang J, Golestani R, Jung JJ, et al. Lipid lowering and imaging protease activation in atherosclerosis. J Nucl Cardiol 2014;21:319-28.
47. Razavian M, Tavakoli S, Zhang J, Nie L, Dobrucki LW, Sinusas AJ, et al. Atherosclerosis plaque heterogeneity and response to therapy detected by in vivo molecular imaging of matrix metalloproteinase activation. J Nucl Med 2011;52:1795-802.
48. Tavakoli S, Razavian M, Zhang J, Nie L, Marfatia R, Dobrucki LW, et al. Matrix metalloproteinase activation predicts amelioration of remodeling after dietary modification in injured arteries. Arterioscler Thromb Vasc Biol 2011;31:102-9.
49. Hyafil F, Vucic E, Cornily JC, Sharma R, Amirbekian V, Blackwell F, et al. Monitoring of arterial wall remodelling in atherosclerotic rabbits with a magnetic resonance imaging contrast agent binding to matrix metalloproteinases. Eur Heart J 2011;32:1561-71.
50. Ouimet T, Lancelot E, Hyafil F, Rienzo M, Deux F, Lemaitre M, et al. Molecular and cellular targets of the MRI contrast agent P947 for atherosclerosis imaging. Mol Pharm 2012;9:850-61.
51. Kolodgie FD, Narula J, Burke AP, Haider N, Farb A, Hui-Liang Y, et al. Localization of apoptotic macrophages at the site of plaque rupture in sudden coronary death. Am J Pathol 2000;157:1259-68.
52. Kietselaer BL, Reutelingsperger CP, Heidendal GA, Daemen MJ, Mess WH, Hofstra L, et al. Noninvasive detection of plaque instability with use of radiolabeled annexin A5 in patients with carotid-artery atherosclerosis. N Engl J Med 2004;350:1472-3.
53. Balasubramanian K, Mirnikjoo B, Schroit AJ. Regulated externalization of phosphatidylserine at the cell surface: Implications for apoptosis. J Biol Chem 2007;282:18357-64.
54. Elliott JI, Surprenant A, Marelli-Berg FM, Cooper JC, Cassady-Cain RL, Wooding C, et al. Membrane phosphatidylserine distribution as a non-apoptotic signalling mechanism in lymphocytes. Nat Cell Biol 2005;7:808-16.
55. Edgington LE, Berger AB, Blum G, Albrow VE, Paulick MG, Lineberry N, et al. Noninvasive optical imaging of apoptosis by caspase-targeted activity-based probes. Nat Med 2009;15:967-73.
56. Mitchell DA, Marletta MA. Thioredoxin catalyzes the S-nitrosation of the caspase-3 active site cysteine. Nat Chem Biol 2005;1:154-8.
57. Hight MR, Cheung YY, Nickels ML, Dawson ES, Zhao P, Saleh S, et al. A peptide-based positron emission tomography probe for in vivo detection of caspase activity in apoptotic cells. Clin Cancer Res 2014;20:2126-35.
58. Reshef A, Shirvan A, Akselrod-Ballin A, Wall A, Ziv I. Small-molecule biomarkers for clinical PET imaging of apoptosis. J Nucl Med 2010;51:837-40.
59. Moreno PR, Purushothaman KR, Fuster V, Echeverri D, Truszczynska H, Sharma SK, et al. Plaque neovascularization is increased in ruptured atherosclerotic lesions of human aorta: Implications for plaque vulnerability. Circulation 2004;110:2032-8.
60. Virmani R, Kolodgie FD, Burke AP, Finn AV, Gold HK, Tulenko TN, et al. Atherosclerotic plaque progression and vulnerability to rupture: Angiogenesis as a source of intraplaque hemorrhage. Arterioscler Thromb Vasc Biol 2005;25:2054-61.
61. Su H, Gorodny N, Gomez LF, Gangadharmath UB, Mu F, Chen G, et al. Atherosclerotic plaque uptake of a novel integrin tracer (18)F-Flotegatide in a mouse model of atherosclerosis. J Nucl Cardiol 2014;21:553-62.
62. Winter PM, Caruthers SD, Zhang H, Williams TA, Wickline SA, Lanza GM. Antiangiogenic synergism of integrin-targeted fumagillin nanoparticles and atorvastatin in atherosclerosis. JACC Cardiovasc Imaging 2008;1:624-34.
63. Razavian M, Marfatia R, Mongue-Din H, Tavakoli S, Sinusas AJ, Zhang J, et al. Integrin-targeted imaging of inflammation in vascular remodeling. Arterioscler Thromb Vasc Biol 2011;31:2820-6.
64. Beer AJ, Pelisek J, Heider P, Saraste A, Reeps C, Metz S, et al. PET/CT imaging of integrin alphavbeta3 expression in human carotid atherosclerosis. JACC Cardiovasc Imaging 2014;7:178-87.
65. Golestani R, Zeebregts CJ, Terwisscha van Scheltinga AG, Lub-de Hooge MN, van Dam GM, Glaudemans AW et al. Feasibility of vascular endothelial growth factor imaging in human atherosclerotic plaque using (89)Zr-bevacizumab positron emission tomography. Mol Imaging 2013;12:235-43.
66. Zhang J, Razavian M, Tavakoli S, Nie L, Tellides G, Backer JM, et al. Molecular imaging of vascular endothelial growth factor receptors in graft arteriosclerosis. Arterioscler Thromb Vasc Biol 2012;32:1849-55.
67. Yu H, Segers F, Sliedregt-Bol K, Bot I, Woltman AM, Boross P, et al. Identification of a novel CD40 ligand for targeted imaging of inflammatory plaques by phage display. FASEB J 2013;27:4136-46.
68. New SE, Goettsch C, Aikawa M, Marchini JF, Shibasaki M, Yabusaki K, et al. Macrophage-derived matrix vesicles: An alternative novel mechanism for microcalcification in atherosclerotic plaques. Circ Res 2013;113:72-7.
69. Otsuka F, Sakakura K, Yahagi K, Joner M, Virmani R. Has our understanding of calcification in human coronary atherosclerosis progressed? Arterioscler Thromb Vasc Biol 2014;34:724-36.
70. Czernin J, Satyamurthy N, Schiepers C. Molecular mechanisms of bone 18F-NaF deposition. J Nucl Med 2010;51:1826-9.
71. Derlin T, Richter U, Bannas P, Begemann P, Buchert R, Mester J, et al. Feasibility of 18F-sodium fluoride PET/CT for imaging of atherosclerotic plaque. J Nucl Med 2010;51:862-5.
72. Dweck MR, Chow MW, Joshi NV, Williams MC, Jones C, Fletcher AM, et al. Coronary arterial 18F-sodium fluoride uptake: A novel marker of plaque biology. J Am Coll Cardiol 2012;59:1539-48.
73. Joshi NV, Vesey AT, Williams MC, Shah AS, Calvert PA, Craighead FH, et al. 18F-fluoride positron emission tomography for identification of ruptured and high-risk coronary atherosclerotic plaques: A prospective clinical trial. Lancet 2014;383:705-13.
74. Motoyama S, Sarai M, Harigaya H, Anno H, Inoue K, Hara T, et al. Computed tomographic angiography characteristics of atherosclerotic plaques subsequently resulting in acute coronary syndrome. J Am Coll Cardiol 2009;54:49-57.
75. Motoyama S, Kondo T, Sarai M, Sugiura A, Harigaya H, Sato T, et al. Multislice computed tomographic characteristics of coronary lesions in acute coronary syndromes. J Am Coll Cardiol 2007;50:319-26.
76. Saam T, Hatsukami TS, Takaya N, Chu B, Underhill H, Kerwin WS, et al. The vulnerable, or high-risk, atherosclerotic plaque: Noninvasive MR imaging for characterization and assessment. Radiology 2007;244:64-77.
77. Sanidas E, Dangas G. Evolution of intravascular assessment of coronary anatomy and physiology: From ultrasound imaging to optical and flow assessment. Eur J Clin Investig 2013;43:996-1008.
78. Stone PH, Saito S, Takahashi S, Makita Y, Nakamura S, Kawasaki T, et al. Prediction of progression of and clinical outcomes using vascular profiling of endothelial shear stress and arterial plaque characteristics: The PREDICTION Study. Circulation 2012;126:172-81.
79. Wald DS, Morris JK, Wald NJ, Chase AJ, Edwards RJ, Hughes LO, et al. Randomized trial of preventive angioplasty in myocardial infarction. N Engl J Med 2013;369:1115-23.
80. Basu S, Hoilund-Carlsen PF, Alavi A. Assessing global cardiovascular molecular calcification with 18F-fluoride PET/CT: Will this become a clinical reality and a challenge to CT calcification scoring? Eur J Nucl Med Mol Imaging 2012;39:660-4.